CORRIGENDUM: Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials. [Pharmacy & Pharmacology. 2025;13(1):31-44. DOI: 10.19163/2307-9266-2025-13-1-31-44]

Abstract

Related to the article: Markin S.S., Ivanov S.V., Beletsky I.P., Zakharova M.V., Ponomarev E.A., Arzamascev E.V. Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials. Pharmacy & Pharmacology. 2025;13(1):31-44. https://doi.org/10.19163/2307-9266-2025-13-1-31-44

We hereby inform readers that changes have been made to the final version of the article in Russian and English.

In the published article " Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials" the authors found an error: randomly, due to a technical error and without any malicious intent, in the "Results" section, subsection "Clinical study of the effect of recombinant non-immunogenic staphylokinase on the formation of specific antibodies and neutralizing activity of patient plasma" (p. 37, second column, 4th paragraph from the top), erroneous numerical indicators were indicated: "In the study of specific antibody titers in patients with STEMI who were administered recombinant non-immunogenic staphylokinase, it was found that 30 (30%) patients did not have specific antibodies. In 70 (70%) patients, specific antibodies were detected with a low titer — in the range of 1/100–1/800."

Correct version: "In the study of specific antibody titers in patients with STEMI who were administered recombinant non-immunogenic staphylokinase, it was found that 70 (70%) patients did not have specific antibodies. In 30 (30%) patients, specific antibodies were detected with a low titer — in the range of 1/100–1/800."

This error is technical in nature, because the abstract text displays correct data, and further in the text of the article correct data are shown: "...neutralizing activity of blood plasma of patients with STEMI who were administered recombinant non-immunogenic staphylokinase revealed that samples from 70 (70%) patients did not have neutralizing activity...".

The error does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.

The authors would like to apologize for any inconvenience.

The authors declare no conflict of interest.

The original article has been updated in the online version: https://www.pharmpharm.ru/jour/article/view/1674